The introduction of respiratory biologics shows greatest benefits in patients with severe and eosinophilic asthma.

Only 15% of patients were adherent to ICS therapy 3 months after their asthma exacerbation, and less that one-fourth of those remained adherent 9 months later. Improved adherence to inhaled ...

The introduction of biologic therapies for severe asthma has transformed clinical practice. Among these agents, benralizumab ...

A 12-week prospective cohort enrolled 73 patients with guideline-based asthma or COPD and no speech-affecting comorbidities, ...

Infections, not eosinophilic inflammation, are the primary cause of asthma exacerbations in patients receiving benralizumab.

Dupilumab significantly reduced the risk of exacerbations compared with placebo in children with moderate to severe asthma, regardless of exacerbation history. Dupilumab was shown to consistently ...

Please provide your email address to receive an email when new articles are posted on . Patients had mild asthma and uncontrolled symptoms. Doses included an albuterol-budesonide combination or ...

A smaller proportion of those with previous- and subsequent-year exacerbations were rated as having well-controlled asthma with AIRQ vs the other 3 assessment modalities. The Asthma Impairment and ...

Please provide your email address to receive an email when new articles are posted on . Global Initiative for Asthma (GINA) guidelines recommend single maintenance and reliever therapy (SMART) for ...

Getting an asthma diagnosis means you have to learn some new lingo. Your doctor may throw around phrases like “peak flow readings” (a way to measure how well your lungs are functioning), “short-acting ...

How does the switch to a high-deductible health plan affect children with asthma? A new study suggests that enrollment in a high-deductible health plan (HDHP) may not be associated with changes in ...